Еве како штити природниот имунитет. Имав и бајги дурги студии на 6, 8 и 12 месеци.
Background Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time. Objective To determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals. Methods...
www.medrxiv.org
In vaccinated subjects, antibody titers decreased by up to 40% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection. Conclusions: This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.
Сите студии за колку штитат вакцинтите се веќе застарени. А се појавуваат и нови истражувања, за која што се надевам ќе излези дека се грешка, оти лошо ни се пишува.
SARS-CoV-2 vaccination is known to induce antibodies that recognize also variants of concerns (VoCs) of the virus. However, epidemiological and laboratory evidences indicate that these antibodies have a reduce neutralization ability against VoCs. We studied binding and neutralizing antibodies...
www.medrxiv.org
И плус ова, сега најново. Нели спајк протеинот од вакцините не прави проблем? Од каде сега бараат лек за тоа?
Ќе излези и за ова антиваксерите биле во право, дека спајк протеинот од вакцините е отров.
In a recent study, we reported that certain anti-spike antibodies of COVID-19 and SARS-CoV viruses can have a pathogenic effect through binding to sick lung epithelium cells and misleading immune responses to attack self-cells. We termed this new pathogenic mechanism “Antibody Dependent...
www.biorxiv.org
A drug candidate for treating adverse reactions caused by pathogenic antibodies inducible by COVID-19 virus and vaccines